Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress

Author(s): Antiopi Voultsiadou, Vasiliki Sarli

Journal Name: Reviews on Recent Clinical Trials

Volume 6 , Issue 3 , 2011

Become EABM
Become Reviewer
Call for Editor


Antimitotic chemotherapy remains the most effective approach to treat a variety of human neoplasms. Since the discovery of tubulin-targeting agents, vinca alkaloids and the taxanes including paclitaxel and docetaxel are used clinically to treat several solid tumors of the head and neck, breast, lung, ovary, and bladder. Despite the preclinical and clinical success of tubulin-targeting agents, the ability of tumors to develop an acquired resistance to drugs used for treatment and neurotoxicity severely limited their long-term effectiveness to cancer cure. Lately, advances in antimitotic treatments led to the identification of novel mitosis-specific agents that are expected to show higher selectivity and less cytotoxicity compared to known antimitotics. This review focuses on the progress of kinesin motor inhibitors that target proteins that function predominantly in mitosis.

Keywords: Antimitotics, Ispinesib, KSP kinesin, Mitotic kinesins, Neoplasms, Taxanes, Tubulin-targeting Agents, vinca alkaloids, paclitaxel

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [271 - 277]
Pages: 7
DOI: 10.2174/157488711796575522
Price: $65

Article Metrics

PDF: 12